Document:

Exhibit
4.2

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

NewAge,
Inc.

 

	Warrant
    Shares: 750,000	 	Issue
    Date: December 1, 2020

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, JGB Management, Inc., or
its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. (New York City time) on
December 1, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from NewAge, Inc.,
a Washington corporation, having its principal place of business at 2420 17th Street, Suite 220, Denver, CO 80202 (the
“Company”), up to 750,000 shares (as subject to adjustment hereunder, the “Warrant Shares”)
of the Company’s Common Stock, as defined in Section 1 herein. The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to the Securities
Purchase Agreement (as defined below) and capitalized terms used herein but not otherwise defined herein shall have the respective
meanings given such terms in the Securities Purchase Agreement.

 

    	1

     

    

 

Section
1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:

 

“Exempt
Issuance” means the issuance of (a) shares of Common Stock or options to employees, consultants, officers or directors
of the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the Board of Directors or the
compensation committee thereof, (b) securities issued pursuant to the Securities Purchase Agreement and/or other securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Warrant, provided that
such securities have not been amended since the date of this Warrant to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities, (c) securities issued pursuant to acquisitions, joint
ventures, partnerships or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business similar to or synergistic with the business of the Company and shall
provide to the Company additional benefits in addition to the investment of funds (which includes under the Merger Agreement),
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or
to an entity whose primary business is investing in securities, (d) shares of Common Stock issued pursuant to the At The Market
Offering Agreement, dated April 30, 2019, by and between the Company and Roth Capital Partners LLC and any other similar at-the-market
offering program entered into or effected by the Company after Issue Date, and (e) shares of Common Stock (not including Common
Stock Equivalents or shares of Common Stock issuable upon exercise or conversion of Common Stock Equivalents) issued in a “public
offering” (within the meaning of IM-5635-3 of the Nasdaq Stock Market Rulebook) under an effective registration statement
on Form S-1 or Form S-3.

 

“Securities
Purchase Agreement” means that certain securities purchase agreement entered into by and among each of the Subsidiary
Guarantors (as defined therein) from time to time a party thereto, each purchaser identified on the signature pages thereto and
the Company, dated as of November 27, 2020.

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice
of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to
the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of
Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within
one (1) Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and
agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder,
the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face
hereof.

 

    	2

     

    

 

b)
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $5.75, subject to adjustment hereunder
(the “Exercise Price”).

 

c)
Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised,
in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

	 	(A)	=	 the Closing Price on the Trading Day immediately preceding
the date of the applicable Notice of Exercise is delivered pursuant to Section 2(a) hereof;

 

	 	(B)	=	 the Exercise Price of this Warrant, as adjusted hereunder;
and

 

	 	(X)	=	 the number of Warrant Shares that would be issuable
upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather
than a cashless exercise.

 

“Closing
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the last sale price of the Common Stock for the date in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.

 

    	3

     

    

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.
The Company agrees not to take any position contrary to this Section 2(c).

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section 2(c).

 

d)
Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise
by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee,
for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder
in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the
Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date,
the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for
all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than
in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver
to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to
the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per
Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard
Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

 

    	4

     

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with
the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such
date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to
the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	5

     

    

 

v.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which transfer taxes and expenses shall
be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.

 

vii.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons,
“Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two (2) Trading
Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms
of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect
to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

    	6

     

    

 

Section
3. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)
Subsequent Equity Sales. If the Company, at any time while this Warrant is outstanding, shall sell or grant any option
to purchase, or sell or grant any right to re-price, or otherwise dispose of or issue (or announce any offer, sale, grant or any
option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than
the Exercise Price then in effect (such issuances collectively, a “Dilutive Issuance”) (it being understood
and agreed that if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation
of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants,
options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at
an effective price per share that is less than the Exercise Price, such issuance shall be deemed to have occurred for less than
the Exercise Price on such date of the Dilutive Issuance at such effective price), then, simultaneously with the consummation
of each Dilutive Issuance, the Exercise Price shall be reduced and only reduced to an amount equal to the product obtained by
multiplying the Exercise Price by a fraction, the numerator of which is the number of shares of Common Stock issued and outstanding
immediately prior to the Dilutive Issuance plus the number of shares of Common Stock which the aggregate offering price for such
Dilutive Issuance would purchase at the then Exercise Price, and the denominator of which shall be the sum of the number of shares
of Common Stock issued and outstanding immediately prior to the Dilutive Issuance plus the number of shares of Common Stock so
issued or issuable in connection with the Dilutive Issuance (such product, the “Base Exercise Price”), and
the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate
Exercise Price of this Warrant shall remain unchanged. Notwithstanding the foregoing, no adjustments shall be made, paid or issued
under this Section 3(b) in respect of an Exempt Issuance. If the Company enters into a Variable Rate Transaction, despite
the prohibition set forth in the Securities Purchase Agreement, the Company shall be deemed to have issued Common Stock or Common
Stock Equivalents at the lowest possible conversion price at which such securities may be converted or exercised. The Company
shall notify the Holder, in writing, no later than two (2) Trading Days following the issuance or deemed issuance of any Common
Stock or Common Stock Equivalents subject to this Section 3(b), indicating therein the applicable issuance price, or applicable
reset price, exchange price, conversion price and other pricing terms (such notice, the “Dilutive Issuance Notice”).
For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 3(b),
upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Warrant Shares based upon the Base
Exercise Price on or after the date of such Dilutive Issuance, regardless of whether the Holder accurately refers to the Base
Exercise Price in the Notice of Exercise.

 

    	7

     

    

 

c)
Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders
of Common Stock evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe
for or purchase any security other than the Common Stock (a “Distribution”), then, upon any exercise of this
Warrant, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of Warrant Shares issued upon such exercise of this Warrant immediately before the date
on which a record is taken for such Warrant, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution. For the term of the Warrant, the Company shall
hold such Distribution for the benefit of the Holder until such time (if any) that the Holder exercises this Warrant or any portion
hereof.

 

d)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons
whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares
of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the
Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the
obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect
as if such Successor Entity had been named as the Company herein.

 

    	8

     

    

 

e)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered
by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register
of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure
to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.

 

    	9

     

    

 

Section
4. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d)
hereof, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole
or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and
funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such
payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading
Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if
properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a
new Warrant issued.

 

b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.

 

    	10

     

    

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)
Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions
or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, to provide to the Company an opinion of counsel, the form and
substance of which opinion shall be reasonably satisfactory to the Company to the effect that the transfer of this Warrant does
not require registration under the Securities Act.

 

e)
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section
5. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting
rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
except as expressly set forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a “cashless
exercise,” and to receive the cash payments contemplated pursuant to Sections 2(d)(i) and 2(d)(iv), in no event will the
Company be required to net cash settle an exercise of this Warrant.

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next
succeeding Trading Day.

 

    	11

     

    

 

d)
Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

    	12

     

    

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement
and defense of this Warrant shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan
(the “New York Courts”). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the
New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served
in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or
proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed
by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding
the fact that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

    	13

     

    

 

h)
Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally
recognized overnight courier service, addressed to the Company, at the address set forth above Attention: Chief Financial Officer
and General Counsel, , email address ggould@newage.com and mdrake@newage.com with a copy to Jeffrey A. Sherman, Faegre Drinker,
Biddle & Reath LLP, 1144 15th Street, Suite 3400, Denver, Colorado 80202, email address: jeff.sherman@faegredrinker.com,
or such other facsimile number, email address or address as the Company may specify for such purposes by notice to the Holders.
Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by facsimile or email, or sent by a nationally recognized overnight courier service addressed to each Holder at the
facsimile number, email address or address of such Holder appearing on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or
communication is delivered via facsimile or email at the facsimile number or email address set forth in this Section prior to
5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile or email at the facsimile number or email address set forth in this Section on a day that is not a
Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of
mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such
notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder of this Warrant, on the other hand.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	14

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	NewAge,
    Inc.
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	15

     

    

 

NOTICE
OF EXERCISE

 

To:
NewAge, Inc.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ]
in lawful money of the United States; or

 

[  ]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under
the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

Name
of Authorized Signatory: ___________________________________________________________________

Title
of Authorized Signatory: ____________________________________________________________________

Date:
________________________________________________________________________________________

 

    	 

     

    

 

EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant
to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 	 
	 	 	(Please
    Print)
	 	 	 
	Address:	 	 
	 	 	(Please
    Print)
	 	 	 
	Phone
    Number:	 	 
	 	 	 
	Email
    Address: 	 	 
	 	 	 
	Dated:
    _______________ __, ______	 	 
	 	 	 
	Holder’s
    Signature:_______________________	 	 
	 	 	 
	Holder’s
    Address:________________________Exhibit
10.1

 

Execution
Version

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of November 30, 2020, between NewAge, Inc., a
Washington corporation (the “Company”), each of the Subsidiary Guarantors from time to time party hereto, and
each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”
and collectively the “Purchasers”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933,
as amended (the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and sell
to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company
as more fully described in this Agreement.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

 

ARTICLE
I.

DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this Section 1.1:

 

“Account
Control Agreement(s)” means any agreement entered into by and among Agent, the Company or any Subsidiary and a third
party bank or other institution (including a securities intermediary) in which the Company or any Subsidiary maintains a deposit
account or an account holding investment property and which grants Agent a perfected first priority security interest in the subject
account or accounts (or any similar agreement or arrangement with respect to deposit accounts located outside of the United States),
and shall include the bank accounts listed on Schedule 1.1A.

 

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Agent”
means JGB Collateral, LLC, in its capacity as collateral agent for the Purchasers.

 

“Ariix”
means Arrix, LLC, a Utah limited liability company, and its consolidated Subsidiaries.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain
closed due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar
orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long
as the electronic funds transfer systems (including for wire transfers) of commercial banks in the State of New York generally
are open for use by customers on such day.

 

    	 

     

    

 

“Class
A Warrants” means the five-year warrants to purchase 750,000 shares of the Common Stock (subject to adjustment for any
stock split, stock dividend, reverse stock split or similar event after the date hereof) at an exercise price per share equal
to the lower of (x) 125% of the VWAP of the Common Stock on the date of this Agreement and (y) $3.75 and substantially in the
form attached hereto as Exhibit A.

 

“Class
B Warrants” means the five-year warrants to purchase 750,000 shares of the Common Stock (subject to adjustment for any
stock split, stock dividend, reverse stock split or similar event after the date hereof) at an exercise price per share equal
to the lower of (x) 200% of the VWAP of the Common Stock on the date of this Agreement and (y) $5.75 and substantially in the
Form attached hereto as Exhibit B.

 

“Closing”
means the closing of the purchase and sale of the Notes hereunder.

 

“Closing
Date” means the Trading Day when each of the conditions to the Closing have been satisfied or waived, but, in any event,
not later than 3 Trading Days after the date of this Agreement.

 

“Closing
Statement” means the form of Closing Statement in the form on Annex A attached hereto.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Commitment
Shares” means 800,000 shares of Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock
split or similar event after the date hereof) to be issued to the Purchasers pursuant to Section 4.1.

 

“Common
Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

 

“Company
Party” means each of the Company and each Material Subsidiary.

 

    	 	2	 

    	 

    

 

“Disclosure
Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.

 

“Effective
Date” means the earliest of the date that (a) the initial Registration Statement has been declared effective by the
Commission, (b) all of the Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement
for the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale
restrictions, (c) following the one year anniversary of the Closing Date provided that a holder of Securities is not an Affiliate
of the Company, or (d) all of the Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities
Act without volume or manner-of-sale restrictions and the Company’s counsel has delivered to such holders a standing written
unqualified opinion that resales may then be made by such holders of the Shares pursuant to such exemption which opinion shall
be in form and substance reasonably acceptable to such holders.

 

“Effectiveness
Deadline” shall have the meaning ascribed to such term in Section 4.1(c).

 

“Evaluation
Date” shall have the meaning ascribed to such term in Section 3.1(s).

 

“Event
of Default” has the meaning set forth in the Note.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Excluded
Subsidiary” means those Subsidiaries that are listed on Schedule 1.1B hereto.

 

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

 

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).

 

“Haynes
and Boone” means Haynes and Boone, LLP, 30 Rockefeller Plaza, 26th Floor, New York, New York 10012.

 

“Indebtedness”
shall have the meaning ascribed to such term in the Notes.

 

“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(p).

 

“Issuer
Repurchase” shall have the meaning ascribed to such term in Section 4.1(c).

 

“Joinder
Agreement” means a Joinder Agreement and Security Agreement Supplement substantially in the form of Exhibit C
hereto

 

    	 	3	 

    	 

    

 

“Legend
Removal Date” shall have the meaning ascribed to such term in Section 4.2(c).

 

“Liens”
shall have the meaning ascribed to such term in the Notes.

 

“Material
Adverse Effect” shall have the meaning ascribed to such term in the Note.

 

“Material
Subsidiary” shall mean all of the Company’s Subsidiaries other than the Excluded Subsidiaries.

 

“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(n).

 

“Merger
Agreement” means the Amended and Restated Agreement and Plan of Merger among the Company, Ariel Merger Sub, LLC, Ariel
Merger Sub 2, LLC, Ariix, certain individuals identified therein and Frederick W. Cooper and the Letter Agreement dated November
16, 2020, amending the Merger Agreement (the “Letter Agreement”).

 

“Notes”
means the 8% Original Issue Discount Senior Secured Notes issued pursuant to this Agreement in the form attached hereto as Exhibit
D.

 

“Obligations”
shall have the meaning ascribed to such term in Section 5.1.

 

“Organizational
Documents” means, with respect to any Person other than a natural person, the documents by which such Person was organized
(such as a certificate of incorporation, certificate of limited partnership or articles of organization, and including, without
limitation, any certificates of designation for preferred stock or other forms of preferred equity) and which relate to the internal
governance of such Person (such as by-laws, a partnership agreement or an operating, limited liability company or members agreement),
including any and all stockholder agreements or voting agreements relating to the capital stock or other equity interests of such
Person

 

“PPP
Loan Contracts” has the meaning set forth in Section 3.1(pp).

 

“PPP
Loans” means that certain unsecured bank loan to Company and its Subsidiaries, dated as of April 14, 2020 in an amount
equal to $6,868,400 borrowed by Company and its Subsidiaries from East West Bank and that certain unsecured bank loan to Ariix,
dated as of May 1, 2020 in an amount equal to $2,765,012 borrowed by Ariix from Bank of America, each under the U.S. Small Business
Administration’s Paycheck Protection Program created by Section 1102 of the Coronavirus Aid, Relief, and Economic Security
Act (Public Law 116-136) (the “CARES Act”).

 

“PPP
Requirements” means, to the extent relating to the Paycheck Protection Program created by Section 1102 of the CARES
Act, (i) the CARES Act, (ii) the Paycheck Protection Program Flexibility Act of 2020 (Public Law 116-142), and (iii) any and all
applicable regulations, ordinances, orders, guidance (including published responses to frequently asked questions), program rules,
or policies promulgated with respect thereto by the U.S. Small Business Administration, U.S. Department of Treasury, Internal
Revenue Service, U.S. Department of Justice, and other agencies with jurisdiction with respect thereto.

 

    	 	4	 

    	 

    

 

“Pay
Off Statement” means a pay-off statement from East West Bank with respect to the repayment in full of all outstanding
obligations under the Loan and Security Agreement dated March 29, 2019, between East West Bank and the Company.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Public
Information Failure” shall have the meaning ascribed to such term in Section 4.3(b).

 

“Public
Information Failure Payments” shall have the meaning ascribed to such term in Section 4.3(b).

 

“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.7.

 

“Registration
Statement” shall have the meaning ascribed to such term in Section 4.1(b).

 

“Repurchase
Notice” shall have the meaning ascribed to such term in Section 4.1(c).

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(h).

 

“Securities”
means the Notes, the Warrants, Warrant Shares and the Commitment Shares.

 

    	 	5	 

    	 

    

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Security
Agreement” means the Security Agreement of event date herewith among the Company and each of its Subsidiaries and the
Agent, as secured party, in the form attached hereto as Exhibit E.

 

“Security
Documents” mean the Security Agreement, Account Control Agreements for each of the Company’s and the Subsidiary
Guarantors’ respective deposits accounts, the Subordination Agreements and any other documents and filing required in order
to grant the Agent a first priority security interest in the assets of the Company and the Subsidiaries, including all UCC-1 financing
statements and all security instruments delivered pursuant to Section 2.4.

 

“Shares”
shall have the meaning ascribed to such term in Section 4.2(c).

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).

 

“Subordination
Agreements” means the subordination agreement with respect to intercompany indebtedness attached hereto as Exhibit
G.

 

“Subscription
Amount” means, as to each Purchaser, its subscription amount as specified below such Purchaser’s name on the signature
page of this Agreement and next to the heading “Subscription Amount,” in United States dollars and in immediately
available funds.

 

“Subsidiary”
means, with respect to the Company, any corporation, partnership, joint venture, limited liability company, trust, variable interest
entity or other entity controlled by the Company or to which the Company is entitled to a majority of the economic benefits of
ownership thereof, directly or indirectly, or through one or more intermediaries, including the entities listed on Exhibit
F and shall, where applicable, also include any direct or indirect Subsidiary formed or acquired after the date hereof.

 

“Subsidiary
Guarantor” means, collectively, (a) each Material Subsidiary of the Company and (b) each Subsidiary established after
the date of this Agreement in accordance with the Note.

 

“Trading
Day” shall mean a day on which the principal Trading Market for the Common Stock is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market
or the New York Stock Exchange (or any successor to any of the foregoing).

 

    	 	6	 

    	 

    

 

“Transaction
Documents” means this Agreement, the Notes, all Security Documents and all exhibits and schedules thereto and hereto
and any other documents or agreements executed in connection with the transactions contemplated hereunder.

 

“Transfer
Agent” means ClearTrust, LLC and any successor transfer agent of the Company.

 

“Variable
Rate Transaction” means a transaction in which the Company or any Subsidiary (a) issues or sells any debt or equity
securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of Common
Stock either (i) at a conversion price, exercise price or exchange rate or other price that varies with the trading prices of
or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities or (i) with a conversion,
exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity
security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company
or the market for the Common Stock or (b) enters into any agreement, including, but not limited to, an equity line of credit,
whereby the Company may issue securities at a future determined price.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a
Trading Day from 9:30 a.m. (local time in New York City, New York) to 4:00 p.m. (local time in New York City, New York)), (b)
if the Common Stock is not then listed or quoted for trading on a Trading Market and if prices for the Common Stock are then reported
in the Pink Open Market, the most recent bid price per share of the Common Stock so reported, or (c) in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably
acceptable to the Company, the reasonable fees and reasonable out-of-pocket expenses of which shall be paid by the Company.

 

“Warrants”
means the Class A Warrants and the Class B Warrants.

 

“Warrant
Shares” means the shares of Common Stock issuable upon exercise of the Warrants.

 

ARTICLE
II.

PURCHASE AND SALE

 

2.1
Closing. Upon the terms and subject to the conditions set forth herein, on the Closing Date the Company agrees to sell,
and the Purchasers, severally and not jointly, agree to purchase, the Notes, which shall have an aggregate principal amount of
$32,432,000. The aggregate Subscription Amount for the Notes shall be $30,000,000. The Notes shall be issued with an aggregate
original issue discount of $2,432,000. Upon satisfaction of the covenants and conditions set forth in this Agreement, the Closing
shall occur at the offices of Haynes and Boone or such other location as the parties shall mutually agree.

 

    	 	7	 

    	 

    

 

2.2
Closing Deliveries.

 

(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

 

(i)
this Agreement duly executed by the Company and each Subsidiary Guarantor;

 

(ii)
a “wet ink” original Note and “wet ink” original Warrants registered in the name of each Purchaser in
accordance with its Subscription Amount;

 

(iii)
the Company shall have provided each Purchaser with the Company’s wire instructions, on Company letterhead and executed
by the Chief Executive Officer or the Chief Financial Officer and an executed Closing Statement;

 

(iv)
the Security Documents duly executed by the Company and each Subsidiary Guarantor, as applicable;

 

(v)
irrevocable instructions to the Transfer Agent instructing the Transfer Agent to reflect the issuance of the Commitment Shares
to the Purchasers on the Closing Date; and

 

(vi)
the Company and each Subsidiary Guarantor that is a Domestic Subsidiary shall have delivered a certificate, executed on behalf
of the Company or such Subsidiary Guarantor, as applicable, by its Secretary, dated as of the Closing Date, certifying the resolutions
adopted by the Board of Directors of the Company or such Subsidiary Guarantor, as applicable, approving the transactions contemplated
by this Agreement and the other Transaction Documents, certifying the current versions of the Company’s or such Subsidiary
Guarantor’s Organizational Documents and certifying as to the signatures and authority of Persons signing the Transaction
Documents and related documents on behalf of the Company or such Subsidiary, as applicable.

 

(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:

 

(i)
this Agreement duly executed by such Purchaser; and

 

(ii)
such Purchaser’s Subscription Amount by wire transfer to the account specified in writing by the Company.

 

    	 	8	 

    	 

    

 

2.3
Closing Conditions.

 

(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

 

(i)
the accuracy in all material respects on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);

 

(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have
been performed; and

 

(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

 

(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions
being met:

 

(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained
herein (unless as of a specific date therein in which case they shall be accurate as of such date);

 

(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;

 

(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;

 

(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and

 

(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the
Closing.

 

    	 	9	 

    	 

    

 

2.4
Post Closing Conditions. The Company shall cause each of the following conditions to be satisfied:

 

(a)
by December 31, 2020, the Company shall deliver or cause to be delivered Account Control Agreements for each of the accounts set
forth on Schedule 1.1A that were not so delivered on the Closing Date; provided that, the Company shall have until January 31,
2021 to move the cash on deposit in any deposit account for which an Account Control Agreement is not delivered by December 31,
2020 to an account subject to an Account Control Agreement and shall maintain no more than $100,000 in any such account not subject
to an Account Control Agreement and $250,000 in the aggregate at all such accounts;

 

(b)
by January 31, 2021, the Company shall use it best efforts to cause (1) the Agent to have perfected, first priority security interest,
Lien and pledge on substantially all of the assets, including all deposit accounts, of (A) Morinda Vietnam, (B) Morinda Sweden
AB, (C) Morinda Norway AS, (D) Morinda Deutschland GmbH, (E) Morinda Magyarorszag Kft (Hungary), (F) [reserved], (G) Morinda International
(Australia) Pty Ltd., (H) Morinda Singapore Pte Ltd., (I) [reserved], (J) Morinda International Tahiti, (K) Morinda Korea, Inc.,
(L) Morinda Worldwide Inc. – Taiwan Branch, (M) Morinda Japan GK, (N) PT Tahitian Noni International, Indonesia, (O) RIIX
Mexico Operations S de RL de CV, (P) Ariix Australia Pty Ltd, (Q) Ariix Canada Operations ULC, (R) Ariix Hong Kong LTD, (S) Ariix
Japan GK, (T) Ariix Europe BV and (U) Ariix Italy SRL, and (2) each of the foregoing Subsidiaries to execute such agreements,
documents and other instruments and to make such filings and take such other steps to give effect to such perfected, first priority
security interest, Lien and pledge on substantially all of their assets; provided, however, by not later than March 31, 2021,
the Company shall have caused the foregoing condition to be satisfied in each jurisdiction where it is legally possible for such
condition to be satisfied.

 

(c)
by January 31, 2021, the Company shall cause Morinda Holdings, Inc. to (1) grant to the Agent a perfected, first priority security
interest, Lien and pledge on 100% of the issued and outstanding equity interests of Tahitian Noni Beverage (China) Company Ltd.
and (2) execute such agreements, documents and other instruments and to make such filings and take such other steps to give effect
to such perfected, first priority security interest, Lien and pledge on such issued and outstanding equity interests of Tahitian
Noni Beverage (China) Company Ltd. (for clarity, as long as the Company has, and has caused its Subsidiaries, to execute such
agreements, instruments and documents, make such filings and take such other steps reasonably requested by Agent in connection
with this Section 2.4(c) prior to January 31, 2021, the failure to receive any governmental approval of such agreements, instruments,
documents and filings by January 31, 2021, shall not cause the failure of this condition to be satisfied, provided, that the Company
shall diligently seek any necessary governmental approval until it has been so received). In addition, the Company shall cause
East West Bank to release any and all liens or security interests it may have over the equity Tahitian Noni Beverage (China) Company
Ltd., or any portion thereof, promptly after the Closing;

 

(d)
by January 31, 2021, the Company shall cause the parent of Ariix (China) Co. Ltd to (1) grant to the Agent a perfected, first
priority security interest, Lien and pledge on 100% of the issued and outstanding equity interests of Ariix (China) Co. Ltd. and
(2) execute such agreements, documents and other instruments and to make such filings and take such other steps to give effect
to such perfected, first priority security interest, Lien and pledge on such issued and outstanding equity interests of Ariix
(China) Co. Ltd. (for clarity, as long as the Company has, and has caused its Subsidiaries, to execute such agreements, instruments
and documents, make such filings and take such other steps reasonably requested by Agent in connection with this Section 2.4(d)
prior to January 31, 2021, the failure to receive any governmental approval of such agreements, instruments, documents and filings
by January 31, 2021, shall not cause the failure of this condition to be satisfied, provided, that the Company shall diligently
seek any necessary governmental approval until it has been so received);

 

    	 	10	 

    	 

    

 

(e)
by January 31, 2021, each Subsidiary referenced in Sections 2.4(b)-(d) shall have delivered a certificate, executed on behalf
of such Subsidiary by its Secretary certifying the resolutions adopted by the Board of Directors of such Subsidiary, as applicable,
approving the transactions contemplated by this Agreement and the other Transaction Documents, certifying the current versions
of the Company’s or such Subsidiary Guarantor’s Organizational Documents and certifying as to the signatures and authority
of Persons signing the Transaction Documents and related documents on behalf of the Company or such Subsidiary, as applicable;

 

(f)
by December 31, 2020, a deed of trust with respect to the real property located at 2410 County Road 100 South, Alamosa, Colorado
81144 granting to the Agent a perfected, first priority security interest in such real property; and

 

(g)
by January 4, 2021, the Company shall have delivered (i) audited financial statements of Ariix for the fiscal years ended December
31, 2019 and December 31, 2018, together with unqualified audit reports relating thereto, and (ii) (1) combined balance sheets
of, statements of operations, comprehensive income (loss) and retained earnings and statements of cash flows of Ariix for the
nine months ended September 30, 2020; (2) combined balance sheets of Ariix’s Subsidiaries, each prepared in accordance with
GAAP; and (3) notes to the foregoing (the financial statements described in clauses (i) and (ii), the “Ariix Financial
Statements”), and such Ariix Financial Statements must demonstrate, in the judgment of the Purchasers, financial performance
of Ariix that is reasonably consistent with the quality of earnings report on Ariix attached hereto as Schedule 2.4(e) and otherwise,
in the reasonable opinion of the Purchasers, validates the Company’s acquisition of Ariix.

 

ARTICLE
III.

REPRESENTATIONS AND WARRANTIES

 

3.1
Representations and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained
in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties
to each Purchaser:

 

(a)
Subsidiaries. As of the date hereof, all of the direct and indirect Subsidiaries of the Company are set forth in the Disclosure
Schedules. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free
and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and
are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. With respect
to each Excluded Subsidiary: (i) it has aggregate assets of less than $200,000, (ii) it has no direct or indirect Subsidiaries
with aggregate asset of more than $200,000 and (iii) the Company’s and its other Subsidiaries’ equity in the revenue
from continuing operations of such Excluded Subsidiary does not exceed 0.5% of the Company’s and its other Subsidiaries
consolidated revenue. The aggregate assets of all the Excluded Subsidiaries does not exceed $2,000,000.

 

    	 	11	 

    	 

    

 

(b)
Organization and Qualification. The Company and each of the Material Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (to the
extent such concepts are applicable in the jurisdiction), with the requisite power and authority to own and use its properties
and assets and to carry on its business as currently conducted. Neither the Company nor any Material Subsidiary is in violation
nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Material Subsidiaries is duly qualified to conduct business and is in good standing
as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be,
would not have or reasonably be expected to result in a Material Adverse Effect.

 

(c)
Authorization; Enforcement. The execution, delivery and performance by each Company Party of the Transaction Documents
to which it is a party are within its powers, have been duly authorized by all necessary action pursuant to its Organizational
Documents. Each of the Transaction Documents to which any Company Party is a party constitutes a valid and binding agreement or
instrument of such Company Party, enforceable against such Company Party in accordance with its respective terms, except as the
enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’
rights generally and by general equitable principles.

 

(d)
No Conflicts. The execution, delivery and performance by each Company Party of the Transaction Documents to which it is
a party do not and will not (i) conflict with or violate any provision of such Company Party’s Organizational Documents,
or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any Lien upon any of the properties or assets of such Company Party (other than Liens in favor
of Agent), or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company
Party debt or otherwise) or other understanding to which such Company Party is a party or by which any property or asset of such
Company Party is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any
law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
such Company Party is subject (including federal and state securities laws and regulations), or by which any property or asset
of such Company Party is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably
be expected to result in a Material Adverse Effect.

 

    	 	12	 

    	 

    

 

(e)
Filings, Consents and Approvals. No Company Party is required to obtain any consent, waiver, authorization or order of,
give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority
or other Person in connection with the execution, delivery and performance by such Company Party of the Transaction Documents
to which it is a party, other than: (i) the filings required pursuant to Section 4.4, (ii) the filing of the Registration Statement
with the Commission pursuant to Section 4.1, (iii) the notice and/or application(s) to each applicable Trading Market for the
issuance and sale of the Warrant Shares and Commitment Shares and the listing thereof for trading on such Trading Market in the
time and manner required thereby and (iv) the filing of Form D with the Commission with respect to the issuance of the Notes and,
if applicable, the Warrants, Warrant Shares and Commitment Shares and such filings as are required to be made under applicable
state securities laws (collectively, the “Required Approvals”).

 

(f)
Issuance of the Warrant Shares and Commitment Shares. The Warrant Shares and Commitment Shares, when issued in accordance
with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens
imposed by the Company other than restrictions on transfer provided for in the Transaction Documents. The Company has reserved
from its duly authorized capital stock shares of Common Stock issuable under the Transaction Documents.

 

(g)
Capitalization. The capitalization of the Company as of the date hereof is as set forth in the Disclosure Schedule. The
Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant
to the exercise of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock
to employees pursuant to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of Common
Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as a result of the issuance of the Securities and under the Merger Agreement,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to
subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common
Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or
any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding
securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange
or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding
securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no
contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem
a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or “phantom stock”
plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none
of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale
of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s
capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s
stockholders.

 

    	 	13	 

    	 

    

 

(h)
SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for the 2 years preceding the date hereof (or such shorter period as the Company was required by law or regulation to
file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective
dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as
applicable, and, to the Company’s knowledge, none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule
144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the
time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in
such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as
of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of
unaudited statements, to normal, immaterial, year-end audit adjustments.

 

(i)
Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements
included within the SEC Reports, except as set forth in the Disclosure Schedules, (i) there has been no event, occurrence or development
that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any
liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business
consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant
to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities
to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending
before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated
by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably
expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties,
operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws
at the time this representation is made or deemed made that has not been publicly disclosed at least one Trading Day prior to
the date that this representation is made.

 

    	 	14	 

    	 

    

 

(j)
Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge
of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by
any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability
of any of the Transaction Documents or the Securities or (ii) would, if there were an unfavorable decision, have or reasonably
be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof,
is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws
or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or
any Subsidiary under the Exchange Act or the Securities Act.

 

(k)
Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such
Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company
and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement
or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not
subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and
its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment
and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

    	 	15	 

    	 

    

 

(l)
Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary
under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation
of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any
of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree,
or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance
or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating
to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters,
except in each case as would not have or reasonably be expected to result in a Material Adverse Effect. Without limiting the generality
of the foregoing, the Company is in material compliance with all federal, state, local and foreign laws and regulations applicable
to the Company’s and its Subsidiaries network marketing program, including, without limitation, the Federal Trade Commission
Act, as amended, and all rules and regulations promulgated thereunder. The Company and its Subsidiaries comply in all material
respects with the U.S. Federal Trade Commission’s Business Guidance Concerning Multi-Level Marketing and its Guides Concerning
the Use of Endorsements and Testimonials in Advertising. The Company and its Subsidiaries maintain policies and procedures regarding
data security, privacy and data use that are commercially reasonable and, in any event, comply in all material respects with the
Company’s and its Subsidiaries’ obligations to its customers and applicable laws, rules and regulations. There have
not been any security breaches of any security policy, data use restriction or privacy breach under any such policies or any applicable
laws, rules or regulations which would have a Material Adverse Effect.

 

(m)
Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws
relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land
surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals,
pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(“Environmental Laws”); (ii) have received all permits licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such
permit, license or approval where, in each case, the failure to so comply would be reasonably expected to have, individually or
in the aggregate, a Material Adverse Effect.

 

    	 	16	 

    	 

    

 

(n)
Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described
in the SEC Reports, except where the failure to possess such permits would not reasonably be expected to result in a Material
Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of
proceedings relating to the revocation or modification of any Material Permit. The Company and its Subsidiaries’ operations
are not subject to the regulations of the U.S. Food and Drug Administration.

 

(o)
Title to Assets. The Company and the Material Subsidiaries have good and marketable title in fee simple to all real property
owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company
and the Material Subsidiaries, in each case free and clear of all Liens, except for Permitted Liens. Any real property and facilities
held under lease by the Company and the Material Subsidiaries are held by them under valid, subsisting and enforceable leases
with which the Company and the Material Subsidiaries are in compliance in all material respects.

 

(p)
Intellectual Property. The Company and the Material Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in
the SEC Reports and which the failure to so have would have a Material Adverse Effect (collectively, the “Intellectual
Property Rights”). None of, and neither the Company nor any Material Subsidiary has received a notice (written or otherwise)
that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate
or be abandoned, within 2 years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the
date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has
any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not have
or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
Company and its Material Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value
of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.

 

(q)
Insurance. The Company and the Material Subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries
are engaged, including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Material Subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.

 

    	 	17	 

    	 

    

 

(r)
Transactions with Affiliates and Employees. None of the officers or directors of the Company or any Subsidiary and, to
the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with
the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or
from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $250,000
other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf
of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.

 

(s)
Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and
regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The
Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that:
(i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and
procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.
The Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such
date, the “Evaluation Date”). Since the Evaluation Date, there have been no changes in the internal control
over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially
affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.

 

    	 	18	 

    	 

    

 

(t)
Certain Fees. Except as set forth on the Disclosure Schedule, no brokerage or finder’s fees or commissions are or
will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall
have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a
type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.

 

(u)
Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
no registration under the Securities Act is required for the offer and sale of the Notes by the Company to the Purchasers as contemplated
hereby.

 

(v)
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Notes,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended. The Company shall conduct its business in a manner so that it will not become an “investment company”
subject to registration under the Investment Company Act of 1940, as amended.

 

(w)
Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the
listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the
foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or and the Company is current in payment of the fees to
the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.

 

(x)
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or
their agents or counsel with any information that it believes constitutes or might constitute material, non-public information.
The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in
securities of the Company. The Disclosure Schedules are true and correct and do not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

 

    	 	19	 

    	 

    

 

(y)
Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Notes hereunder, (i) the fair saleable value of the Company’s
assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small
capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. The Disclosure Schedule sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the
Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. Neither the Company nor any Subsidiary
is in default with respect to any Indebtedness.

 

(z)
Tax Status. The Company and its Subsidiaries each (i) has made or filed all material United States federal, state and local
income and all material foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which
it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined
to be due on such returns, reports and declarations excluding taxes which are being contested and for which reserves have been
set aside in accordance with GAAP and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in
any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary
know of no basis for any such claim excluding taxes which are being contested and for which reserves have been set aside in accordance
with GAAP.

 

(aa)
No General Solicitation. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of
the Notes by any form of general solicitation or general advertising.

 

(bb)
Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for
unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)
made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties
or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made
by any person acting on its behalf of which the Company is aware) which is in violation of law in any material respect or (iv)
violated in any material respect any provision of FCPA.

 

    	 	20	 

    	 

    

 

(cc)
Accountants. The Company’s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion
with respect to the financial statements to be included in the Company’s Annual Report for the fiscal year ending December
31, 2020.

 

(dd)
No Disagreements with Accountants. There are no disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise, between the Company and the accountants formerly or presently employed by the Company and the Company
is current with respect to any fees owed to its accountants which could affect the Company’s ability to perform any of its
obligations under any of the Transaction Documents.

 

(ee)
Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the
transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby
and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction
Documents and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities.
The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement and the other
Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company
and its representatives.

 

(ff)
Acknowledgment Regarding Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary
notwithstanding (except for Sections 3.2(e) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none
of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling,
long and/or short, securities of the Company, or “derivative” securities based on securities issued by the Company
or to hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically
including, without limitation, Short Sales or “derivative” transactions, before or after the closing of this or future
private placement transactions, may negatively impact the market price of the Company’s publicly-traded securities, (iii)
any Purchaser, and counter-parties in “derivative” transactions to which any such Purchaser is a party, directly or
indirectly, presently may have a “short” position in the Common Stock and (iv) each Purchaser shall not be deemed
to have any affiliation with or control over any arm’s length counter-party in any “derivative” transaction.
The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times
during the period that the Securities are outstanding and (z) such hedging activities (if any) could reduce the value of the existing
stockholders’ equity interests in the Company at and after the time that the hedging activities are being conducted. The
Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.

 

    	 	21	 

    	 

    

 

(gg)
Stock Option Plans. Each stock option granted by the Company under the Company’s stock option plan was granted (i)
in accordance with the terms of the Company’s stock option plan and (ii) with an exercise price at least equal to the fair
market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock
option granted under the Company’s stock option plan has been backdated. The Company has not knowingly granted, and there
is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate
the grant of stock options with, the release or other public announcement of material information regarding the Company or its
Subsidiaries or their financial results or prospects.

 

(hh)
Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

 

(ii)
U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s
request.

 

(jj)
Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of
1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no Action or Proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company or any Subsidiary, threatened.

 

(kk)
No Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive
officer, other officer of the Company, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities,
calculated on the basis of voting power (each, an “Issuer Covered Person” and, together, “Issuer Covered
Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule
506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a
Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e),
and has furnished to the Purchasers a copy of any disclosures provided thereunder.

 

    	 	22	 

    	 

    

 

(ll)
Other Covered Persons. Other than as set forth on the Disclosure Schedule, the Company is not aware of any person (other
than any Issuer Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers
in connection with the sale of any Notes.

 

(mm)
Notice of Disqualification Events. The Company will notify the Purchasers in writing, prior to the Closing Date of (i)
any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become
a Disqualification Event relating to any Issuer Covered Person.

 

(nn)
Merger Agreement. The copy of the Merger Agreement filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K
dated October 1, 2020, and the copy of the Letter Agreement attached to the Company’s Current Report on Form 8-K dated November
16, 2020, are true, accurate and complete copies of the Merger Agreement and Letter Agreement. There has been no amendment, modification
or waiver of any of the terms and provisions of the Merger Agreement other than pursuant to the Letter Agreement. The transactions
contemplated by the Merger Agreement have been consummated prior to the date hereof. Other than the payment of (a) $10,000,000
to the Members (as defined in the Merger) pursuant to Section 1(a) of the Letter Agreement the Company does not have any obligation
to pay any cash consideration or other cash payments to the Members or any other Person pursuant to the Merger Agreement. Without
the prior consent of the Purchasers, the Company shall not amend, modify or waive any provision of the Merger Agreement or the
Letter Agreement in a manner that would increase the cash consideration payable by the Company or any Subsidiary thereunder or
otherwise be adverse to the interests of the Purchasers.

 

(oo)
No Integrated Offering. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would cause this offering of the Commitment Shares and Warrants to be integrated with prior offerings by the Company for
purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company
are listed or designated.

 

(pp)
PPP Loans. Except with respect to the PPP Loans, neither Company nor any of its Subsidiaries have applied for or received
any stimulus funds or programs, benefits, deferrals or any other kind of remuneration in connection with the COVID-19 pandemic
or any issues relating thereto. Company and Ariix applied for and received the PPP Loans in accordance with all PPP Requirements.
Company and its Subsidiaries used the proceeds of the PPP Loans only to satisfy costs and expenses described in Section 1106(b)
of the CARES Act and have made a good faith effort to maximize the amount of the PPP Loan that may be forgiven pursuant to Section
1106 of the CARES Act (as modified by the PPP Flexibility Act). Each contract evidencing the PPP Loans (the “PPP Loan
Contracts”) are in full force and effect and are the legal, valid and binding obligation of Company and its Subsidiaries,
and of the other parties thereto enforceable against each of them in accordance with its terms. Neither Company nor any of its
Subsidiaries is in default under any PPP Loan Contract, nor neither is any other party to any PPP Loan Contract in breach of or
default thereunder, and no event has occurred that with or without the lapse of time or the giving of notice or both would constitute
a breach or default on Company or any other party thereunder. No party to any of the PPP Loan Contracts has exercised any termination
rights with respect thereto, and no party has given notice of any significant dispute with respect to any PPP Loan Contract. Company
and its Subsidiaries have complied in all respects with all terms and conditions of each PPP Loan Contract. Company, in good faith,
reasonably anticipates that the PPP Loan will be forgiven.

 

    	 	23	 

    	 

    

 

3.2
Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents
and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein,
in which case they shall be accurate as of such date):

 

(a)
Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership,
limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the
Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction
Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized
by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser.
Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser
in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against
it in accordance with its terms, except as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors’ rights generally.

 

(b)
Own Account. Such Purchaser understands that the Notes are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
and not with a view to or for distributing or reselling such Securities in violation of the Securities Act or any applicable state
securities law. Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.

 

(c)
Purchaser Status. At the time such Purchaser was offered the Notes, it was, and as of the date hereof it is, an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act.

 

    	 	24	 

    	 

    

 

The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such
Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement or any representations
and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transactions contemplated hereby.

 

ARTICLE
IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1
Commitment Shares and Warrants. 

 

(a)
The Company shall issue to the Purchasers (pro rata in accordance with the relative Subscription Amounts of the Purchasers) the
Commitment Shares and the Warrants on the Closing Date. The Commitment Shares and Warrants are fully earned by the Purchasers
on the Closing Date and are non-refundable.

 

(b)
The resale of the Commitment Shares and Warrant Shares will be registered for resale on a new resale registration statement on
Form S-3 (the “Registration Statement”) which shall be filed by the Company with the Commission, at the Company’s
sole expense, not later than January 31, 2021. The Company shall use its best efforts to cause such Registration Statement to
be declared effective by the Commission at the earliest practicable time and to remain continuously effective. The Company shall
also (i) prepare and file with the Commission such amendments and supplements to such Registration Statement and the prospectus
used in connection therewith as may be necessary to keep such Registration Statement continuously effective and to comply with
the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement
in accordance with the Purchasers intended method of disposition, (ii) use its commercially reasonable efforts to register or
qualify the securities covered by such Registration Statement under the securities or blue sky laws of such jurisdictions as the
Purchasers may reasonably request; and (iii) notify each Purchaser when the prospectus or any prospectus supplement or post-effective
amendment has been filed, and, with respect to such Registration Statement or any post-effective amendment, when the same has
become effective, of any request by the Commission for amendments or supplements to such Registration Statement or to amend or
to supplement such prospectus or for additional information or of the issuance by the Commission of any stop order suspending
the effectiveness of such Registration Statement or the initiation of any proceedings for that purpose.

 

(c)
If the Registration Statement has not been declared effective by the Commission March 31, 2021 (the “Effectiveness Deadline”),
then commencing on the Effectiveness Deadline until the Registration Statement has been declared effective by the Commission,
the Purchasers shall have the option to require the Company, at any time and from time to time, in one or more transactions, to
repurchase all or a portion of the Commitment Shares (an “Issuer Repurchase”) by delivering a written notice
to the Company (which may be by e-mail) (a “Repurchase Notice”). The purchase price for the Commitment Shares
shall be the greater of (i) the VWAP for the Common Stock on the Trading Day immediately preceding the date of the Repurchase
Notice and (ii) the VWAP for the Common Stock on the date of this Agreement. Each Issuer Repurchase shall be executed on the date
of the applicable Repurchase Notice.

 

    	 	25	 

    	 

    

 

4.2
Transfer Restrictions.

 

(a)
The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of
Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser
or in connection with a pledge as contemplated in Section 4.2(b), the Company may require the transferor thereof to provide to
the Company an opinion of counsel selected by the transferor, the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities
Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall
have the rights and obligations of a Purchaser under this Agreement.

 

(b)
The Purchasers agree to the imprinting, so long as is required by this Section 4.2, of a legend on any of the Securities in the
following form:

 

NEITHER
THIS SECURITY [NOR THE SECURITIES ISSUABLE HEREUNDER] HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF
COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY
[AND THE SECURITIES ISSUABLE HEREUNDER] MAY BE PLEDGED WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR”
AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN.

 

The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a
registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited
investor” as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such
Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be
subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required
in connection therewith. Further, no notice shall be required of such pledge. The Company will execute and deliver such reasonable
documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the
Securities, including, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities
Act or other applicable provision of the Securities Act to appropriately amend the list of selling stockholders thereunder.

 

    	 	26	 

    	 

    

 

(c)
The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser promptly after the Effective
Date if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively.
If all or any portion of a Warrant is exercised into Warrant Shares at a time when there is an effective registration statement
to cover the resale of such Warrant Shares, or if such Warrant Shares may be sold under Rule 144 following any “cashless”
exercise of such Warrants, or if such legend is not otherwise required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free
of all legends. The Company agrees that following the Effective Date or at such time as such legend is no longer required under
this Section 4.2(c), it will, no later than 2 Trading Days following the delivery by a Purchaser to the Company or the Transfer
Agent of a certificate representing Shares, as the case may be, issued with a restrictive legend (such date, the “Legend
Removal Date”), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free
from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer
Agent that enlarge the restrictions on transfer set forth in this Section 4.2. Certificates for Commitment Shares and Warrant
Shares (collectively, “Shares”) subject to legend removal hereunder shall be transmitted by the Transfer Agent to
the Purchaser by crediting the account of the Purchaser’s prime broker with the Depository Trust Company System as directed
by such Purchaser.

 

(d)
If the Company fails to (a) issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate
representing the Shares so delivered to the Company by such Purchaser that is free from all restrictive and other legends and
(b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock
to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale
of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such Purchaser
anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such Purchaser’s
total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock
so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the “Buy-In Price”)
over the product of (A) such number of Shares that the Company was required to deliver to such Purchaser by the Legend Removal
Date multiplied by (B) the any sale price of the Common Stock selected by such Purchaser (including any intra-day price) on any
Trading Day during the period commencing on the date of the delivery by such Purchaser to the Company of the applicable Shares
(as the case may be) and ending on the date of such delivery and payment under this clause (ii).

 

    	 	27	 

    	 

    

 

(e)
Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any
Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery
requirements, or an exemption therefrom, and that if Shares are sold pursuant to a Registration Statement, they will be sold in
compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates
representing Shares as set forth in this Section 4.2 is predicated upon the Company’s reliance upon this understanding.

 

(f)
The Purchasers’ rights and remedies set forth in this Section 4.2 are in addition to, and not in limitation, of any other
rights and remedies set forth in the Transaction Documents, under law or in equity.

 

4.3
Furnishing of Information; Public Information.

 

(a)
Until the time that no Purchaser owns Securities, the Company covenants to maintain the registration of the Common Stock under
Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company
is not then subject to the reporting requirements of the Exchange Act. Without limiting the generality foregoing, the Company
shall file (i) a Current Report on Form 8-K regarding the consummation of its acquisition of Ariix which includes the financial
statements and pro forma financial information required by sections (a) and (b) of Item 9.01 of Form 8-K by not later than January
31, 2021, and (ii) its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 by not later than March 15, 2021
(and will not seek extensions in respect of the filing thereof under Rule 12b-25 promulgated under the Exchange Act or under any
conditional exemptions from the reporting requirements of the Exchange Act ordered by the Commission in response to the COVID-19
pandemic or otherwise).

 

(b)
At any time during the period commencing from the 6 month anniversary of the date hereof and ending at such time that all of the
Shares may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction
or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement
under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes such an issuer in the future, and
the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a “Public Information Failure”)
then, in addition to such Purchaser’s other available remedies, the Company shall pay to a Purchaser, in cash, as partial
liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an
amount in cash equal to 0.10% of the aggregate Subscription Amount of such Purchaser’s Notes on the day of a Public Information
Failure and on every thirtieth (30th) day (prorated for periods totaling less than 30 days) thereafter until the earlier
of (a) the date such Public Information Failure is cured and (b) such time that such public information is no longer required
for the Purchasers to transfer the Shares pursuant to Rule 144. The payments to which a Purchaser shall be entitled pursuant to
this Section 4.3(b) are referred to herein as “Public Information Failure Payments.” Public Information Failure
Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments
are incurred and (ii) the third (3rd) Business Day after the event or failure giving rise to the Public Information
Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such
Public Information Failure Payments shall bear interest at the rate of 1% per month (prorated for partial months) until paid in
full. Nothing herein shall limit such Purchaser’s right to pursue actual damages for the Public Information Failure, and
such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief.

 

    	 	28	 

    	 

    

 

4.4
Securities Laws Disclosure; Publicity. The Company shall (a) by 9:00 a.m. (New York time) on the Closing Date, issue a
press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K,
including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From
and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all
material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their
respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents.
In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their
respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates
on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases
with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release
nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any
Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall
not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the
Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission
or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal
securities law in connection with (i) any registration statement contemplated by the Registration Rights Agreement and (ii) the
filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading
Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under
this clause (b).

 

4.5
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor
any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes,
or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have
consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.
To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser’s consent,
the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of
its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any
of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis
of, such material, non-public information. To the extent that any notice provided pursuant to any Transaction Document constitutes,
or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

 

    	 	29	 

    	 

    

 

4.6
Use of Proceeds. The Company shall use the net proceeds from the sale of the Notes hereunder as set forth in Schedule 4.6
and the Company shall not use such proceeds: (a) for the redemption of any Common Stock or Common Stock Equivalents, (b) for the
settlement of any outstanding litigation or (c) in violation of FCPA or OFAC regulations. The Company covenants and agrees that
it shall pay the Six-Month Anniversary Cash Consideration (as defined in the Merger Agreement) in shares of Common Stock.

 

4.7
Indemnification of Purchasers. Subject to the provisions of this Section 4.7, the Company will indemnify and hold each
Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls
such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser
Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses,
including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation
that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations,
warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, (b) any action
instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder or
creditor of the Company or any other Person, with respect to any of the transactions contemplated by the Transaction Documents
(unless such action is solely based upon a material breach of such Purchaser Party’s representations, warranties or covenants
under the Transaction Documents or any violations by such Purchaser Party of state or federal securities laws or any conduct by
such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct), or (c)
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or supplements thereto; (d) the omission or alleged omission
to state in the Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments
or supplements, a material fact required to be stated therein, or necessary to make the statements therein not misleading; or
(e) any violation or alleged violation by the Company of the Securities Act, any federal or state securities law or any rule or
regulation promulgated under the Securities Act or any federal or state securities law in connection with the offering covered
by the Registration Statement. If any action shall be brought against any Purchaser Party in respect of which indemnity may be
sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have
the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser
Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees
and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof
has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume
such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict
on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable
to any Purchaser Party under this Agreement for any settlement by a Purchaser Party effected without the Company’s prior
written consent, which shall not be unreasonably withheld or delayed. The indemnification required by this Section 4.7 shall be
made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any
Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.

 

    	 	30	 

    	 

    

 

4.8
Reservation of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue Warrant Shares upon exercise of the Warrants.

 

4.9
Listing of Common Stock. The Company hereby agrees to use its best efforts to maintain the listing or quotation of the
Common Stock on the Trading Market on which it is currently listed or quoted, and concurrently with the Closing, the Company shall
apply to list or quote all of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading
Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will
then include in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares
to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably
necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the
Company’s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to
maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established
clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established
clearing corporation in connection with such electronic transfer.

 

4.10
Variable Rate Transaction. From the date hereof until none of the Warrants remain outstanding, the Company shall be prohibited
from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock
or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction other than the at-the-market
offering program contemplated by the At The Market Offering Agreement, dated April 30, 2019, by and between the Company and Roth
Capital Partners LLC and any other similar at-the-market offering program entered into or effected by the Company after the date
hereof. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy
shall be in addition to any right to collect damages.

 

    	 	31	 

    	 

    

 

4.11
Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that neither it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or
sales, including Short Sales, of any of the Company’s securities during the period commencing with the execution of this
Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to
the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the
initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms
of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing and notwithstanding
anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes
any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press
release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any
securities of the Company, including Short Sales, in accordance with applicable securities laws from and after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in
Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company
to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4.

 

4.12
Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation
D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers
at the Closing under applicable securities or “Blue Sky” laws of the states of the United States and shall provide
evidence of such actions promptly upon request of any Purchaser.

 

ARTICLE
V.

GUARANTY

 

5.1
The Guaranty. Each Subsidiary Guarantor hereby, jointly and severally, guarantees to the Purchasers, as primary obligor
and not as surety, the prompt payment of all present and future debt, liabilities and obligations of the Company owing to the
Purchasers, or any Person entitled to indemnification hereunder, or any of their respective successors, permitted transferees
or permitted assigns, arising under or in connection with this Agreement, the Note or any other Transaction Document in full when
due (whether at stated maturity, as a mandatory prepayment, by acceleration, as a mandatory cash collateralization or otherwise)
(the “Obligations”) strictly in accordance with the terms thereof. Each Subsidiary Guarantor hereby further
agrees that if any of the Obligations are not paid in full when due (whether at stated maturity, as a mandatory prepayment, by
acceleration, or otherwise), the Subsidiary Guarantors will promptly pay the same, without any demand or notice whatsoever, and
that in the case of any extension of time of payment or renewal of any of the Obligations, the same will be promptly paid in full
when due (whether at extended maturity, as a mandatory prepayment, by acceleration, as a mandatory cash collateralization or otherwise)
in accordance with the terms of such extension or renewal.

 

    	 	32	 

    	 

    

 

5.2
Obligations Unconditional. The obligations of the Subsidiary Guarantors under this Article V are joint and several, absolute
and unconditional, irrespective of the value, genuineness, validity, regularity or enforceability of any of the Transaction Documents,
or any other agreement or instrument referred to therein, or any substitution, release, impairment or exchange of any other guarantee
of or security for any of the Obligations, and, to the fullest extent permitted by applicable law, irrespective of any other circumstance
whatsoever which might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor (other than the
payment in full of the Obligations), it being the intent of this Section 5.2 that the obligations of the Subsidiary Guarantors
hereunder shall be absolute and unconditional under any and all circumstances. Each Subsidiary Guarantor agrees that it shall
have no right of subrogation, indemnity, reimbursement or contribution against the Company or any other guarantor for amounts
paid under this Article V until such time as the Purchasers have been paid in full in respect of all Obligations, and no Person
or governmental authority shall have any right to request any return or reimbursement of funds from the Purchasers in connection
with monies received under the Transaction Documents. Without limiting the generality of the foregoing, it is agreed that, to
the fullest extent permitted by law, the occurrence of any one or more of the following shall not alter or impair the liability
of each Subsidiary Guarantor hereunder which shall remain absolute and unconditional as described above: (a) at any time or from
time to time, without notice to any Subsidiary Guarantor, the time for any performance of or compliance with any of the Obligations
shall be extended, or such performance or compliance shall be waived; (b) any of the acts mentioned in any of the provisions of
any of the Transaction Documents, or any other agreement or instrument referred to in the Transaction Documents shall be done
or omitted; (c) the maturity of any of the Obligations shall be accelerated, or any of the Obligations shall be modified, supplemented
or amended in any respect, or any right under any of the Transaction Documents, or any other agreement or instrument referred
to in the Transaction Documents shall be waived or any other guarantee of any of the Obligations or any security therefor shall
be released, impaired or exchanged in whole or in part or otherwise dealt with; or (d) any of the Obligations shall be determined
to be void or voidable (including, without limitation, for the benefit of any creditor of any Subsidiary Guarantor) or shall be
subordinated to the claims of any Person (including, without limitation, any creditor of any Subsidiary Guarantor). With respect
to its obligations hereunder, each Subsidiary Guarantor hereby expressly waives diligence, presentment, demand of payment, protest
and all notices whatsoever, and any requirement that the Purchasers exhaust any right, power or remedy or proceed against any
Person under any of the Transaction Documents, or any other agreement or instrument referred to in the Transaction Documents,
or against any other Person under any other guarantee of, or security for, any of the Obligations. Without limiting any of the
foregoing, each Subsidiary Guarantor waives all suretyship defenses and other defenses to enforcement of this Article V.

 

    	 	33	 

    	 

    

 

5.3
Reinstatement. The obligations of the Subsidiary Guarantors under this Article V shall be automatically reinstated if and
to the extent that for any reason any payment by or on behalf of any Person in respect of the Obligations is rescinded or must
be otherwise restored by any holder of any of the Obligations, whether as a result of any proceedings in bankruptcy or reorganization
or otherwise, and each Subsidiary Guarantor agrees that it will indemnify the Purchasers on demand for all reasonable costs and
expenses (including, without limitation, the reasonable and documented out of pocket fees and expenses of counsel) incurred by
the Purchasers in connection with such rescission or restoration, including any such costs and expenses incurred in defending
against any claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy,
insolvency or similar law.

 

5.4
Certain Additional Waivers. Each Subsidiary Guarantor further agrees that it shall have no right of recourse to security
for the Obligations except, following the payment in full of all Obligations, through the exercise of rights of subrogation pursuant
to Section 5.2 and through the exercise of rights of contribution pursuant to Section 5.7.

 

5.5
Remedies. Each Subsidiary Guarantor agrees that, to the fullest extent permitted by law, as between the Subsidiary Guarantor,
on the one hand, and the Purchasers, on the other hand, the Obligations may be declared to be forthwith due and payable as provided
in Section 5(b) of the Note (and shall be deemed to have become automatically due and payable in the circumstances provided in
said Section 5(b) of the Note) for purposes of Section 5.1 notwithstanding any stay, injunction or other prohibition preventing
such declaration (or preventing the Obligations from becoming automatically due and payable) as against any other Person and that,
in the event of such declaration (or the Obligations being deemed to have become automatically due and payable), the Obligations
(whether or not due and payable by any other Person) shall forthwith become due and payable by the Subsidiary Guarantors for purposes
of this Article V.

 

5.6
Guarantee of Payment; Continuing Guarantee. The guarantee in this Article V is a guaranty of payment and not of collection,
is a continuing guarantee, and shall apply to all Obligations whenever arising.

 

5.7
Limitations on Guaranty. Each Subsidiary Guarantor and the Purchasers hereby confirms that it is its intention that the
guarantee provided for in this Article V not constitute a fraudulent transfer or conveyance for purposes of the U.S. Bankruptcy
Code, the Uniform Fraudulent Conveyance Act or any similar federal or state law. To effectuate the foregoing intention, each Subsidiary
Guarantor and the Purchasers hereby irrevocably agrees that the guarantee of the Obligations by each such Guarantor provided for
in this Article V shall be limited to an amount as will, after giving effect to such maximum amount and all other (contingent
or otherwise) liabilities of such Guarantor that are relevant under such laws and after giving effect to any rights to contribution
provided in Section 5.8 or pursuant to any agreement providing for an equitable contribution among such Subsidiary Guarantor and
the other Subsidiary Guarantors, result in the Obligations guaranteed by such Subsidiary Guarantor in respect of such maximum
amount not constituting a fraudulent transfer or conveyance under Section 548 of the U.S. Bankruptcy Code, the Uniform Fraudulent
Conveyance Act or any comparable federal or state law.

 

    	 	34	 

    	 

    

 

5.8
Contribution. Subject to Section 5.2, each Subsidiary Guarantor hereby agrees that to the extent that a Subsidiary Guarantor
shall have paid more than its proportionate share of any payment made hereunder, such Subsidiary Guarantor shall be entitled to
seek and receive contribution from and against any other Subsidiary Guarantor hereunder which has not paid its proportionate share
of such payment. Each Subsidiary Guarantor’s right of contribution shall be subject to the terms and conditions of Section
5.2. The provisions of this Section 5.8 shall in no respect limit the obligations and liabilities of any Subsidiary Guarantor
to the Purchasers and each Subsidiary Guarantor shall remain liable to the Purchasers for the full amount guaranteed by such Subsidiary
Guarantor hereunder.

 

5.9
New Subsidiaries. Within ten (10) Business days (or such later date as the Purchaser may agree in its sole discretion)
after any Person becomes a direct or indirect Subsidiary of the Company or any other Company Party, whether by formation, acquisition
or otherwise, the Company shall cause such Person to (i) become a Subsidiary Guarantor and to grant a lien on its assets by becoming
a “Debtor” or “Grantor” party to the Security Agreement, by executing and delivering to the Agent and
the Purchasers a Joinder Agreement in form and substance satisfactory to the Purchasers, and (iii) deliver to the Purchaser such
charter documents, resolutions and favorable opinions of counsel reasonably requested by the Purchaser with respect to such new
Subsidiary (which shall cover, among other things, the legality, validity, binding effect and enforceability of the documentation
referred to in the immediately preceding clauses (i) through (ii)), all in form, content and scope reasonably satisfactory to
the Purchasers.

 

ARTICLE
VI.

MISCELLANEOUS

 

6.1
Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only
and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other
parties, if the Closing has not been consummated on or before the 3rd Trading Day following the date hereof; provided,
however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).

 

6.2
Fees and Expenses. The Company shall deliver to the Purchasers, prior to the Closing, a completed and executed copy of
the Closing Statement, attached hereto as Annex A. The Company shall pay all Transfer Agent fees (including, without limitation,
any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.
In addition, the Company hereby agrees to pay on demand: (a) all costs and expenses of the Purchasers in connection with the preparation,
negotiation, execution, and delivery of the Transaction Documents and any and all amendments, modifications, renewals, extensions,
and supplements thereof and thereto, including, without limitation, the reasonable fees and expenses of legal counsel, advisors,
consultants, and auditors for the Purchasers, (b) all costs and expenses of the Purchasers in connection with any Event of Default
under the Note and the enforcement of the Transaction Documents, including, without limitation, the fees and expenses of legal
counsel, advisors, consultants, and auditors for the Purchasers, (c) all costs, expenses, assessments, and other charges incurred
in connection with any filing, registration, recording, or perfection of any security interest or Lien contemplated by the Transaction
Documents, and (d) all other costs and expenses incurred by Purchasers in connection with Transaction Documents, any litigation,
dispute, suit, proceeding or action; the enforcement of their rights and remedies, protection of their interests in bankruptcy,
insolvency or other legal proceedings, including, without limitation, all costs, expenses, and other charges (including the Purchasers’
internal charges) incurred in connection with evaluating, observing, collecting, examining, auditing, appraising, selling, liquidating,
or otherwise disposing of any collateral for the Obligations.

 

    	 	35	 

    	 

    

 

6.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral
or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

6.4
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication
is delivered via email at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is
delivered via email at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day
or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the 2nd Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is
required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.
To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K.

 

6.5
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in principal amount
of the Notes based on the aggregate Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely
impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition
or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise
of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations
of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent
of such adversely affected Purchaser. Any amendment effected in accordance with this Section 6.5 shall be binding upon each Purchaser
and holder of Securities and the Company.

 

    	 	36	 

    	 

    

 

6.6
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.

 

6.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. Neither the Company nor any Subsidiary Guarantor may not assign this Agreement or any rights or obligations
hereunder or delegate any of its obligations hereunder without the prior written consent of each Purchaser (other than by merger).
Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers
any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the
provisions of the Transaction Documents that apply to the “Purchasers.”

 

6.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as
otherwise set forth in Section 4.7 and this Section 6.8.

 

6.9
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a
party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to
the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including
with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action
or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

6.10
Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

 

6.11
Execution. This Agreement may be executed in 2 or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other
party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof.

 

    	 	37	 

    	 

    

 

6.12
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

6.13
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under
a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then
such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant
notice, demand or election in whole or in part without prejudice to its future actions and rights.

 

6.14
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances
shall also pay or provide for any reasonable third-party costs (including a customary indemnity) associated with the issuance
of such replacement Securities.

 

6.15
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The
parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations
contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any
such obligation the defense that a remedy at law would be adequate.

 

6.16
Payment Set Aside. To the extent that the Company or any Subsidiary Guarantor makes a payment or payments to any Purchaser
pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments
or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or
preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company
or any such Subsidiary Guarantor, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy
law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation
or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment
had not been made or such enforcement or setoff had not occurred.

 

    	 	38	 

    	 

    

 

6.17
Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under
the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated
damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial
liquidated damages or other amounts are due and payable shall have been canceled.

 

6.18
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

6.19
Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity
to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to
be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto.

 

6.20
Usury. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now
or at any time hereafter in force, in connection with any claim, action or proceeding that may be brought by any Purchaser in
order to enforce any right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in
any Transaction Document, it is expressly agreed and provided that the total liability of the Company under the Transaction Documents
for payments in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum
Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of them,
when aggregated with any other sums in the nature of interest that the Company may be obligated to pay under the Transaction Documents
exceed such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to the Transaction
Documents is increased or decreased by statute or any official governmental action subsequent to the date hereof, the new maximum
contract rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from the effective date
thereof forward, unless such application is precluded by applicable law. If under any circumstances whatsoever, interest in excess
of the Maximum Rate is paid by the Company to any Purchaser with respect to indebtedness evidenced by the Transaction Documents,
such excess shall be applied by such Purchaser to the unpaid principal balance of any such indebtedness or be refunded to the
Company, the manner of handling such excess to be at such Purchaser’s election.

 

6.21
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER
PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 

 

(Signature
Pages Follow)

 

    	 	39	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	COMPANY:	 	 
	 	 	 
	NEWAGE,
    INC.	 	Address
    for Notice:
	 	 	 	 	 
	By:
    	/s/
    Greg Gould	 	Email:
    	Greg_Gould@newage.com
	Name: 
    	Greg
    Gould	 	 	 
	Title:
    	Chief
    Financial Officer	 	 	 
	 	 	 	 	 
	With
    a copy to (which shall not constitute notice):	 	 	 

 

	Jeffrey
    A. Sherman	 
	Partner	 
	jeff.sherman@faegredrinker.com	 
	Connect:
    vCard / LinkedIn	 
	 	 
	+1
    303 607 3666 direct / +1 303 877 3383 mobile	 
	 	 
	Faegre
    Drinker	 
	1144
                                         15th Street, Suite 3400

        Denver,
        Colorado 80202, USA
	 

 

SUBSIDIARY
GUARANTORS:

 

Address
for Notice:

2420
17th Street, Suite 220

Denver,
CO 80202

Email:
GGould@newage.com

 

With
a copy to (which shall not constitute notice):

Jeffrey
A. Sherman, Partner

Email:
jeff.sherman@faegredrinker.com

Faegre
Drinker

1144
15th Street, Suite 3400

Denver,
Colorado 80202, USA

 

    	 	 	 

    	 

    

 

Ariel
Merger Sub 2, LLC

Morinda
Magyarorszag KFT (Hungary)

Morinda
Hong Kong Limited

Morinda
Sweden AB

Morinda
Norway AS

Morinda
International (Australia) PTY Ltd.

Morinda
Singapore PTE. Ltd.

Morinda
Korea, Inc.

 

	By:
    	/s/
    Brent D. Willis	 
	Name:
    	Brent
    D. Willis	 

 

As
Manager of Ariel Merger Sub 2, LLC

As
Managing Director of Morinda Magyarorszag KFT (Hungary)

As
Authorized Signatory of Morinda Hong Kong Limited

As
Director of Morinda Sweden AB and Morinda Norway AS

As
Director of Morinda International (Australia) PTY Ltd. and Morinda Singapore PTE. Ltd.

As
President of Morinda Korea, Inc.

 

    	 	 	 

    	 

    

 

NABC,
Inc.

NABC
Properties, LLC

Morinda
Holdings, Inc.

Morinda
JAPAN GK

PT
Tahitian Noni International, Indonesia

PT
Morinda Independent

Morinda
Deutschland GMBH

 

	By:
    	/s/
    Gregory A. Gould	 
	Name:
    	Gregory
    A. Gould	 

 

As
Authorized Signatory of NABC, Inc.; PT Tahitian Noni International, Indonesia; PT

Morinda
Independent; Morinda Deutschland GMBH,

As
Chief Financial Officer of the sole member of NABC Properties, LLC

As
Chief Financial Officer of Morinda Holdings, Inc.

As
Executive Manager of Morinda JAPAN GK

 

    	 	 	 

    	 

    

 

Tropical
Resources, Inc.

Morinda
Inc.

Morinda
USA, Inc.

Morinda
Access, Inc.

Morinda
Worldwide, Inc

Morinda
International Holding Co, Inc.

Morinda
International Asia, Inc.

 

	By:
    	/s/
    Carl A. Aure	 
	Name:
    	Carl
    A. Aure	 
	Title:
    	Sr.
    VP, Finance & Taxation	 

 

	Morinda
    Worldwide Mexico SRL	 
	 	 	 
	By:
    	/s/
    Carl A. Aure	 
	Name:
    	Carl
    A. Aure	 
	Title:
    	Supervisory
    Officer	 
	 	 	 
	Morinda
    International Tahiti	 
	Morinda
    Vietnam	 
	 	 	 
	By:
    	/s/
    Carl A. Aure	 
	Name:
    	Carl
    A. Aure	 
	Title:
    	Legal
    Representative	 

 

    	 	 	 

    	 

    

 

	Tahitian
    Noni Beverages (China) Ltd.	 
	 	 	 
	By:	/s/
    Kevin Ma	 
	Name:	Kevin
    Ma	 
	Title:	General
    Director	 

 

    	 	 	 

    	 

    

 

	Morinda
    Worldwide Chile Limitada	 
	 	 	 
	By:
    	/s/
    David Garcia	 
	Name:
    	David
    Garcia	 
	Title:
    	Legal
    Representative	 

 

    	 	 	 

    	 

    

 

Ariix
Holdings LLC

Ariix
Inc.

Ariix
Korea Ltd.

Ariix
Europe B.V.

Ariix
UK Ltd.

Hong
Kong Services Ltd.

Ariix
Taiwan Ltd

Riix
Mexico Operations S. de R.L.

Riix
Mexico Services (Imports) S. de R.L.

Ariix
Hong Kong Ltd.

Ariix
China Ltd.

Ariix
Italy S.R.L.

Ariix
Canada Operations ULC

Ariix
Australia PTY Ltd.

Ariix
Shanghai Trading Co.

 

	By:
    	/s/
    Jeffrey A. Yates	 
	Name:
    	Jeffrey
    A. Yates	 

 

As
Manager of Ariix Holdings LLC; Ariix Taiwan Ltd

As
Authorized Signatory of Ariix, Inc.

As
Legal Representative of Ariix Korea Ltd.; Ariix China Ltd.; Ariix Shanghai Trading Co

As
Director of Ariix Europe B.V.; Ariix UK Ltd.; Hong Kong Services Ltd.; Riix Mexico Operations S. de R.L.; Riix Mexico Services
(Imports) S. de R.L.; Ariix Hong Kong Ltd.; Ariix Italy S.R.L.; Ariix Canada Operations ULC; Ariix Australia PTY Ltd.

 

    	 	 	 

    	 

    

 

	Ariix
    Japan GK	 
	 	 	 
	By:
    	/s/
    Fred W. Cooper	 
	Name:
    	Fred
    W. Cooper	 
	Title:
    	Executive
    Manager	 

 

    	 	 	 

    	 

    

 

	Ariix
    Zth G.K.	 
	 	 	 
	By:
    	/s/
    Scott E. Schwindiman	 
	Name:
    	Scott
    E. Schwindiman	 
	Title:
    	Executive
    Manager	 

 

    	 	 	 

    	 

    

 

	Ariix
    Ireland Ltd.	 
	 	 	 
	By:
    	/s/
    Brandon John	 
	Name:
    	Brandon
    John	 
	Title:
    	Director	 

 

    	 	 	 

    	 

    

 

	Ariix
    Malta Holdings Ltd.	 
	Ariix
    Malta Ltd.	 
	 	 	 
	By:
    	/s/
    Tyler B. Jones	 
	Name:
    	Tyler
    B. Jones	 
	Title:
    	Director	 

 

    	 	 	 

    	 

    

 

	Morinda
    Worldwide Peru S.R.L.	 
	 	 	 
	By:
    	/s/
    Renzo Chacon	 
	Name:
    	Renzo
    Chacon	 
	Title:
    	Manager	 

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE
PAGE FOR PURCHASER FOLLOWS]

 

    	 	 	 

    	 

    

 

[PURCHASER
SIGNATURE PAGES TO NEWAGE SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	Name
    of Purchaser:	JGB
    Capital LP

 

	Signature
    of Authorized Signatory of Purchaser:	/s/
    Brett Cohen

 

	Name
    of Authorized Signatory:	Brett
    Cohen

 

	Title
    of Authorized Signatory:	President

 

	Email
    Address of Authorized Signatory: 	bcohen@jgbcap.com

 

Address
for Notice to Purchaser:

 

c/o
JGB Management, Inc.

21
Charles Street

Westport,
CT 06880

 

Address
for Delivery of Securities to Purchaser (if not same as address for notice):

 

c/o
JGB Management, Inc.

21
Charles Street

Westport,
CT 06880

 

Subscription
Amount: $2,000,000

Principal
amount of Notes: $2,162,133

Commitment
Shares: 53,333

Class
A Warrants: 50,000

Class
B Warrants: 50,000

 

[SIGNATURE
PAGES CONTINUE]

 

    	 	 	 

    	 

    

 

[PURCHASER
SIGNATURE PAGES TO NEWAGE SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	Name
    of Purchaser:	JGB
    Partners LP

 

	Signature
    of Authorized Signatory of Purchaser:	/s/
    Brett Cohen

 

	Name
    of Authorized Signatory:	Brett
    Cohen

 

	Title
    of Authorized Signatory:	President

 

	Email
    Address of Authorized Signatory:	bcohen@jgbcap.com

 

Address
for Notice to Purchaser:

 

c/o
JGB Management, Inc.

21
Charles Street

Westport,
CT 06880

 

Address
for Delivery of Securities to Purchaser (if not same as address for notice):

 

c/o
JGB Management, Inc.

21
Charles Street

Westport,
CT 06880

 

Subscription
Amount: $19,228,485

Principal
amount of Notes: $20,787,274

Commitment
Shares: 512,760

Class
A Warrants: 480,712

Class
B Warrants: 480,712

 

    	 	 	 

    	 

    

 

[PURCHASER
SIGNATURE PAGES TO NEWAGE SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	Name
    of Purchaser:	JGB
    Capital Offshore Ltd.

 

	Signature
    of Authorized Signatory of Purchaser:	/s/
    Brett Cohen

 

	Name
    of Authorized Signatory:	Brett
    Cohen

 

	Title
    of Authorized Signatory:	President

 

	Email
    Address of Authorized Signatory:	bcohen@jgbcap.com

 

Address
for Notice to Purchaser:

 

c/o
JGB Management, Inc.

21
Charles Street

Westport,
CT 06880

 

Address
for Delivery of Securities to Purchaser (if not same as address for notice):

 

c/o
JGB Management, Inc.

21
Charles Street

Westport,
CT 06880

 

Subscription
Amount: $7,500,000

Principal
amount of Notes: $8,108,000

Commitment
Shares: 200,000

Class
A Warrants: 187,500

Class
B Warrants: 187,500

 

    	 	 	 

    	 

    

 

[PURCHASER
SIGNATURE PAGES TO NEWAGE SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	Name
    of Purchaser:	JGB
    Plymouth Rock LLC

 

	Signature
    of Authorized Signatory of Purchaser:	/s/
    Brett Cohen

 

	Name
    of Authorized Signatory:	Brett
    Cohen

 

	Title
    of Authorized Signatory:	President

 

	Email
    Address of Authorized Signatory:	bcohen@jgbcap.com

 

Address
for Notice to Purchaser:

 

c/o
JGB Management, Inc.

21
Charles Street

Westport,
CT 06880

 

Address
for Delivery of Securities to Purchaser (if not same as address for notice):

 

c/o
JGB Management, Inc.

21
Charles Street

Westport,
CT 06880

 

Subscription
Amount: $1,271,515

Principal
amount of Notes: $1,374,592

Commitment
Shares: 33,907

Class
A Warrants: 31,788

Class
B Warrants: 31,788

 

    	 	 	 

    	 

    

 

Annex
A 

 

CLOSING
STATEMENT

 

Pursuant
to the attached Securities Purchase Agreement, dated as of the date hereto, the purchasers shall purchase Notes from NewAge, Inc.,
a Washington corporation (the “Company”). Funds payable by the Purchasers in the amount of $30,000,000 at the
Closing will be disbursed in accordance with this Closing Statement.

 

Disbursement
Date: December __, 2020

 

	I.
                                         SUSCRIPTION PAYMENT

         
	 
	Gross
    Proceeds to be Received 	$
	 	 
	II.
                                         DISBURSEMENTS

         
	 
	 	$
	 	$
	 	$
	 	$
	 	$
	 	 
	Total
    Amount Disbursed:	$

 

WIRE
INSTRUCTIONS:

Please
see attached.

 

Acknowledged
and agreed to

this
___ day of _________, _____

 

	NEWAGE,
    INC. 	 
	 	 	 
	By:
    	      	 
	Name:	 	 
	Title:	 	 

 

    	 	56	 

    	 

    

 

Exhibit
A

 

Form
of Class A Warrant

 

    	 	57	 

    	 

    

 

Exhibit
B

 

Form
of Class B Warrant

 

    	 	58	 

    	 

    

 

EXHIBIT
C

JOINDER
AGREEMENT AND SECURITY AGREEMENT SUPPLEMENT

 

THIS
JOINDER AGREEMENT AND SECURITY AGREEMENT SUPPLEMENT (this “Agreement”) dated as of ______________ [Date], is
by and among (i) _______________ [NAME OF NEW SUBSIDIARY], a _____________ (“New Subsidiary”), (ii) NEWAGE,
Inc., a Washington corporation (the “Company”), and (iii) JGB Collateral, LLC, as agent (the “Agent”).

 

WHEREAS,
the New Subsidiary and the Company are required to enter into this Agreement for the benefit of the Purchaser pursuant to that
certain Securities Purchase Agreement, dated as of November 30, 2020 (as amended, restated, supplemented or otherwise modified
from time to time, the “Purchase Agreement”), by and among the Company, certain subsidiaries of the Company party
thereto as Subsidiary Guarantors and the Purchasers (as defined in the Purchase Agreement). Capitalized terms used herein and
not defined herein shall have the meanings specified in the Purchase Agreement or, if not defined therein, in the applicable Transaction
Document.

 

NOW
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

 

Section
1. Joinder to Note Documents. New Subsidiary hereby acknowledges, agrees and confirms that, by its execution of this Agreement,
New Subsidiary shall be deemed to be a party to the following Note Documents: (a) the Purchase Agreement as a “Subsidiary
Guarantor” and an “Company Party” as such terms are used therein (including, without limitation, the guaranty
contained in Article V of the Purchase Agreement) and (b) the Security Agreement as a “Subsidiary Guarantor” and a
“Debtor” and a “Grantor” as such terms are used therein, in each case, for all purposes and shall have
all of the obligations of a “Subsidiary Guarantor”, “Company Party”, “Grantor” and “Debtor”,
as applicable, thereunder as if it had executed each such Transaction Document. New Subsidiary hereby ratifies, as of the date
hereof, and agrees to be bound by, all of the terms, provisions and conditions applicable to it as a “Subsidiary Guarantor”,
“Company Party”, “Grantor” and “Debtor” contained in the above referenced Transaction Documents.
Without limiting the generality of the foregoing terms of this Section 1, New Subsidiary: (i) pursuant to Article V of the Purchase
Agreement, hereby jointly and severally guarantees to the Purchasers, as primary obligor and not as surety, the prompt payment
of the Obligations in full when due (whether at stated maturity, as a mandatory prepayment, by acceleration or otherwise) strictly
in accordance with the terms thereof and (ii) pursuant to the Security Agreement hereby grants a continuing lien and security
interest on its Collateral (as such term is defined in the Security Agreement) in favor of the Agent under the Security Agreement
as security for the payment and performance of all of the Secured Obligations (as such term is defined in the Security Agreement).

 

    	 	59	 

    	 

    

 

Section
2. New Subsidiary hereby represents and warrants to the Purchaser that: (i) set forth on Schedule 1 hereto is New Subsidiary’s
chief executive office, principal place of business and, if applicable, organization identification number as of the date hereof;
(ii) set forth on Schedule 2 hereto are the locations of all inventory, goods, equipment and other tangible assets of New Subsidiary
(other than inventory in transit in connection with a bona fide sales transaction) as of the date hereof; (iii) set forth on Schedule
3 hereto are the locations of all deposit accounts and securities accounts of New Subsidiary, including the name and address of
the depository bank or securities intermediary, as applicable, and the account number as of the date hereof; (iv) set forth on
Schedule 4 hereto is a list of all Intellectual Property of New Subsidiary that is registered or recorded (or which is the subject
of an application for registration or recordation) in the United States, any state or territory thereof, or in any other country
or any political subdivision thereof as of the date hereof; (v) New Subsidiary does not own any real property as of the date hereof;
(vi) the exact legal name and jurisdiction of organization of New Subsidiary is as set forth in the preamble to this Agreement;
(vii) Subsidiary has not during the five years preceding the date hereof (A) changed its legal name, (B) changed its jurisdiction
of formation, or (C) been party to a merger, consolidation or other change in structure; (viii) set forth on Schedule 5 hereto
is a description of all Commercial Tort Claims by or in favor of New Subsidiary seeking damages in excess of $50,000 in any individual
instance or $100,000 in the aggregate, and (ix) New Subsidiary has no Subsidiaries as of the date hereof.

 

Section
3. Miscellaneous.

 

(a)
The address of New Subsidiary for purposes of all notices and other communications is the address set forth for the Company the
Purchase Agreement.

 

(b)
New Subsidiary hereby waives acceptance by the Purchaser of the guaranty by such New Subsidiary in Article V of the Purchase Agreement.

 

(c)
This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including
by telecopy or other electronic transmissions, e.g. .pdf), and all of said counterparts taken together shall be deemed to constitute
one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or electronic
transmission shall be effective as delivery of a manually executed counterpart of this Agreement.

 

(d)
This Agreement shall be deemed and shall constitute a “Transaction Document” as such term is defined in the Purchase
Agreement.

 

Section
4. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE
PRINCIPLES THEREOF REGARDING CONFLICTS OF LAWS).

 

[SIGNATURE
PAGES TO FOLLOW]

 

    	 	60	 

    	 

    

 

IN
WITNESS WHEREOF, each of the parties hereto has caused this Joinder Agreement and Security Agreement Supplement to be duly executed
by its authorized officers, and the Purchaser, has caused the same to be accepted by its authorized officer, as of the day and
year first above written.

 

	[NEW
    SUBSIDIARY]	 
	 	 	 
	By:	             	 
	Name:	 	 
	Title:	 	 

 

    	 	61	 

    	 

    

 

Exhibit
D

 

Form
of Note

 

    	 	62	 

    	 

    

 

Exhibit
E

 

Form
of Security Agreement

 

    	 	63	 

    	 

    

 

Exhibit
F

 

Subsidiaries

 

Excluded
Subsidiaries:

 

	 	1.	Morinda
    Exotic Juices, Inc.
	 	2.	Pure
    Fruit Technologies LLC
	 	3.	Mangostana,
    LLC
	 	4.	Morinda
    Agricultural Products, Inc.
	 	5.	New
    Age Brasil Bemestar Limitada
	 	6.	Morinda
    Malaysia (M) SDN, BHD
	 	7.	Morinda
    Worldwide Colombia Ltda.
	 	8.	Morinda
    UK, Ltd
	 	9.	Morinda
    Poland Spoika Z Organiczona Odpowiedzialnoscia 
	 	10.	Morinda
    Italia S.R.L.
	 	11.	Morinda
    New Zealand Limited
	 	12.	NewAge
    Trurkey Icecek Urunleri Itcaret Limited Sirketi
	 	13.	Newage
    Ecuador
	 	14.	Morinda
    NewAge Nigeria Limited
	 	15.	New
    Age (China) Biological Technology LTD
	 	16.	New
    Age (Shanghai) Biological Technology Ltd
	 	17.	LLC
    Morinda RUS
	 	18.	Morinda
    Canada Co.
	 	19.	Morinda
    de Mexico SRL De CV
	 	20.	Morinda
    Worldwide Thailand LTD.
	 	21.	Morinda
    International French Polynesia
	 	22.	Ariix
    International, Inc. - UT
	 	23.	Travel
    Destinations International LLC – DE
	 	24.	Ariix
    Thailand
	 	25.	Ariix
    Hong Kong Holdings Ltd
	 	26.	Ariix
    CIS Ltd.
	 	27.	Ariix
    Healthy Living (Israel) PTY

 

Material
Subsidiaries:

 

	 	1.	Ariix,
    LLC – Ariel Merger Sub 2, LLC
	 	2.	NABC,
    Inc. - CO
	 	3.	NABC
    Properties, LLC - CO
	 	4.	Morinda
    Holdings, Inc. - UT
	 	5.	Tropical
    Resources, Inc. - UT
	 	6.	Tahitian
    Noni Beverages (China) Ltd.
	 	7.	Morinda
    Inc. - UT
	 	8.	Morinda
    USA, Inc.- UT
	 	9.	Morinda
    JAPAN GK
	 	10.	PT
    Tahitian Noni International, Indonesia
	 	11.	PT
    Morinda Indepden

 

    	 	64	 

    	 

    

 

	 	12.	Morinda
    Deutschland GMBH
	 	13.	Morinda
    Magyarorszag KFT (Hungary)
	 	14.	Morinda
    Access, Inc.- UT
	 	15.	Morinda
    Worldwide, Inc. - UT
	 	16.	Morinda
    Hong Kong Limited
	 	17.	Morinda
    Worldwide Mexico SRL
	 	18.	Morinda
    Worldwide Peru S.R.L.
	 	19.	Morinda
    Worldwide Chile Limitada
	 	20.	Morinda
    International Holding Co, Inc. - UT
	 	21.	Morinda
    International Tahiti
	 	22.	Morinda
    International Asia, Inc.- UT
	 	23.	Ariel
    Merger Sub 2, LLC – UT
	 	24.	Morinda
    Vietnam
	 	25.	Morinda
    Sweden AB
	 	26.	Morinda
    Norway AS
	 	27.	Morinda
    International (Australia) PTY Ltd.
	 	28.	Morinda
    Singapore PTE. LTD.
	 	29.	Morinda
    Korea, Inc.
	 	30.	Ariix
    Holdings LLC - UT
	 	31.	Ariix
    Inc. - DE
	 	32.	Ariix
    Korea Ltd.
	 	33.	Ariix
    Europe B.V.
	 	34.	Ariix
    Japan GK
	 	35.	Ariix
    UK Ltd
	 	36.	Hong
    Kong Services Ltd.
	 	37.	Ariix
    Taiwan Ltd
	 	38.	Riix
    Mexico Operations S. de R.L.
	 	39.	Riix
    Mexico Services (Imports) S. de R.L.
	 	40.	Ariix
    Hong Kong Ltd
	 	41.	Ariix
    China Ltd.
	 	42.	Ariix
    Zth G.K.
	 	43.	Ariix
    Italy S.R.L.
	 	44.	Ariix
    Ireland Ltd
	 	45.	Ariix
    Canada Operations ULC
	 	46.	Ariix
    Australia PTY Ltd
	 	47.	Ariix
    Shanghai Trading Co.
	 	48.	Ariix
    Malta Holdings Ltd.
	 	49.	Ariix
    Malta Ltd.

 

    	 	65	 

    	 

    

 

Exhibit
G

 

Form
of Subordination Agreement

 

    	 	66

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]